Trial Profile

An Evaluation of BAT 8010 for Injection in Combination With BAT 1006 in Locally Advanced or Metastatic Entities Safety, Tolerability, Pharmacokinetic Profile, and Initial Clinical Efficacy of the Tumor in Patients Multicenter, Open Phase Ib/IIa Clinical Study

Status: Recruiting

Phase of Trial: Phase I/II

Latest Information Update: 17 Apr 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs BAT 1006 (Primary) ; BAT-8010 (Primary)
Indications Adenocarcinoma; Biliary cancer; Bladder cancer; Breast cancer; Colorectal cancer; Gastric cancer; Male breast cancer; Non-small cell lung cancer; Oesophageal cancer; Pelvic cancer; Ureteral neoplasms; Urethral cancer; Urogenital cancer
Focus Adverse reactions; Therapeutic Use
Sponsors Bio-Thera Solutions

14 Apr 2025 According to Bio-Thera Solutions media release, data from this study will be presented at at the 2025 ASCO Annual Meeting
07 Mar 2025 Planned primary completion date changed from 24 Dec 2024 to 9 Nov 2026.
18 Oct 2024 Planned number of patients changed from 108 to 216.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com